BioTime (BTX -0.2%) says its shareholders have overwhelmingly approved the planned acquisition...

|By:, SA News Editor

BioTime (BTX -0.2%) says its shareholders have overwhelmingly approved the planned acquisition of stem cell-related assets from Geron (GERN). The green light was given at a special meeting of shareholders, with at least 32.5M votes coming in favor from the 34.5M shares represented and voted.